Remove about
article thumbnail

Everything You Wanted to Know About Expanded Access but Were Afraid to Ask, Part 2

Bill of Health

The 21 st Century Cures Act (passed in 2016) recommends the use of RWD to support FDA decision-making about product approvals. While RCTs are considered the “gold standard” for generating evidence about a product’s safety and efficacy, RWD can supplement RCT results. Identifying biomarkers.

FDA 176
article thumbnail

FDA Oversight of AI Software Developed by Health Care Providers

Health Law Advisor

But the question is, to what extent do health care providers need to worry about FDA requirements as they use AI? FDA has been regulating machine learning algorithms used in a clinical context for decades. The allure is obvious. 1] As of last Fall, the list included 521 products dating back to 1995. Very brief.

FDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How Will New FDA Hearing Aid Regulations Impact Health Plans?

HIT Consultant

First, let’s examine the new regulatory framework the FDA established. Health plans offering the OTC benefit can also leverage the opportunity to educate members about the significant role hearing aids can play in improving their overall health. About Thomas Tedeschi. Epub 2016 Aug 23. Introducing OTC hearing aids.

FDA 98
article thumbnail

How pharmaceutical marketing affects decisions about patient care

Kaiser Permanente

Pharmaceutical marketing aims to shape perceptions about a drug’s benefits and harms, and this can significantly impact providers’ decisions about patient care. In 2016, the 12 largest pharmaceutical companies spent more than $120 billion on marketing , compared to $75 billion on research and development.

article thumbnail

Patient Support Isn’t Just About the Price of Therapy: It’s About Safety, Really Rich Data and Trust

Health Populi

When I talk about patient support programs (PSPs), I’m most often focused on supporting peoples’ access to medicines due to costs, bolstering health literacy, and addressing health citizens’ risks of drivers of health that can be obstacles to optimal health outcomes (those challenging social determinants of health).

article thumbnail

Unpacking Averages: The Difference Between Data and the Truth: Comparing FDA’s UDI Database with FDA’s 510(k) Database

Health Law Advisor

I thought this month might be an opportunity to show how two different FDA databases produce quite different results when they should be the same. For context, I should explain that I didn’t set out to find differences in the FDA data sets. I don’t know why, and frankly I hope the FDA changes that. Background.

FDA 98
article thumbnail

FDA Issues Warnings About Research Participant Protections and Inadequate Sterilization of Medical Equipment to Mayo Clinic Care Network Hospital

The Health Law Firm

Board Certified by The Florida Bar in Health Law On April 12, 2016, the US Food and Drug Administration (FDA) issued warnings that targeted the allegedly substandard protection of research participants at a hospital in the Mayo Clinic Care Network. Below are the enforcement actions taken by the FDA. By George F. Indest III, J.D.,

FDA 40